Nektar Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Nektar Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NKTR
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.
CEOHoward W. Robin
CEOHoward W. Robin
Employees61
Employees61
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded1990
Founded1990
Employees61
Employees61
NKTR Key Statistics
Market cap1.17B
Market cap1.17B
Price-Earnings ratio-7.27
Price-Earnings ratio-7.27
Dividend yield—
Dividend yield—
Average volume651.07K
Average volume651.07K
High today$57.86
High today$57.86
Low today$54.75
Low today$54.75
Open price$56.81
Open price$56.81
Volume464.38K
Volume464.38K
52 Week high$66.92
52 Week high$66.92
52 Week low$6.48
52 Week low$6.48
Stock Snapshot
Nektar Therapeutics(NKTR) stock is priced at $57.69, giving the company a market capitalization of 1.17B. It carries a P/E multiple of -7.27.
As of 2025-12-04, Nektar Therapeutics(NKTR) stock has fluctuated between $54.75 and $57.86. The current price stands at $57.69, placing the stock +5.4% above today's low and -0.3% off the high.
Nektar Therapeutics(NKTR) shares are trading with a volume of 464.38K, against a daily average of 651.07K.
During the past year, Nektar Therapeutics(NKTR) stock moved between $6.48 at its lowest and $66.92 at its peak.
During the past year, Nektar Therapeutics(NKTR) stock moved between $6.48 at its lowest and $66.92 at its peak.
Analyst ratings
89%
of 9 ratingsBuy
88.9%
Hold
11.1%
Sell
0%
People also own
Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.